(H. Lee Moffitt Cancer Center&Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant.

Related Links:

Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study, Published online: 05 February 2018; doi:10.1038/s41409-018-0105-9Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study

Source: Bone Marrow TransplantationCategory: Hematology Authors: Source Type: research

Acute myeloid leukemia (AML) is an aggressive malignancy where despite improvements in conventional chemotherapy and bone marrow transplantation, overall survival remains poor. Sphingosine kinase 1 (SPHK1) generates the bioactive lipid sphingosine 1-phosphate (S1P) and has established roles in tumor initiation, progression, and chemotherapy resistance in a wide range of cancers. The role and targeting of SPHK1 in primary AML, however, has not been previously investigated. Here we show that SPHK1 is overexpressed and constitutively activated in primary AML patient blasts but not in normal mononuclear cells. Subsequent targe…

Source: BloodCategory: Hematology Authors: Tags: Myeloid Neoplasia Source Type: research

Abstract
Patients with Down syndrome (DS) are predisposed to acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in early and later childhood, respectively, but rarely experience both. We herein discuss four patients with DS with ALL and a history of AML who were treated with various chemotherapies, one of whom later received a bone marrow transplantation. Three patients survived and remain in remission. One patient died of fulminant hepatitis during therapy. No common cytogenetic abnormalities in AML and ALL besides constitutional +21 were identified, indicating that the two leukemia types were independent…

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors: Tags: Brief Report Source Type: research

Fanconi anemia (FA) is a primarily autosomal recessive, bone marrow failure syndrome caused by mutations in 1 of more than 19 genes in the FA/BRCA DNA damage response pathway, which makes individuals with FA prone to cancer. The syndrome is diagnosed at a median age of 7 years, often because of recognition of aplastic anemia and the presence of a characteristic constellation of developmental abnormalities, including short stature, caf é-au-lait spots, absent radii, and hypoplastic thumbs [1]. Patients with FA are at particularly high risk of severe bone marrow failure (BMF), acute myelogenous leukemia (AML), and sol…

Some 200 students in the Class of 2016 will receive their medical degrees June 3 during the Hippocratic Oath Ceremony for the David Geffen School of Medicine at UCLA. Earning an M.D. requires grueling hours, demanding classes and unwavering focus. The following students hurdled enormous obstacles to achieve that goal, making their accomplishments all the more remarkable.
Teen mother overcomes lifetime of abuse to achieve M.D.
Rebecca Lopez, 37, from Covina in the San Gabriel Valley, survived childhood abuse, became a mother at age 14 and endured a violent marriage, but never surrendered her dream of becoming a doctor….

In this study, we investigated the antileukemia activity of a MEK1 and FLT3 dual inhibitor, E6201, in AML cells resistant to FLT3 inhibition. We found that E6201 exerted profound apoptogenic effects on AML cells harboring resistance-conferring FLT3 mutations. This activity appeared to be p53 dependent, and E6201-induced cytotoxicity was retained under hypoxic culture conditions and during coculture with mesenchymal stem cells that mimic the AML microenvironment. Furthermore, E6201 markedly reduced leukemia burden and improved the survival of mice in a human FLT3–mutated AML model. Collectively, our data provide a pre…

Source: Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Therapeutics, Targets, and Chemical Biology Source Type: research

Abstract

Background
Dysregulation of miRNAs that can act as tumor suppressors or oncogenes can result in tumorigenesis. Previously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and targets podocalyxin and discoidin domain receptor 1. Herein we investigated the functional role of miR-199b in AML and its prognostic implications.

Methods
Major approaches include transduction of hematopoietic stem cells and bone marrow transplantation, analyses of blood lineages, histone deacetylases (HDAC) inhibitors, a…

In conclusion, mutations responsible for GCV resistance was detected in 6.6% (2/30) of immunocompromised patients receiving GCV, indicating that the determination of CMV antiviral drug resistance may help clinicians for planning the antiviral therapy.
PMID: 26313280 [PubMed – in process]

Source: Mikrobiyoloji BulteniCategory: Microbiology Tags: Mikrobiyol Bul Source Type: research

In this study, we supplemented mice with eicosapentaenoic acid (EPA, C20:5), a polyunsaturated omega-3 fatty acid, at pharmacologic levels, to examine whether the endogenous metabolite, cyclopentenone prostaglandin delta-12 PGJ3 (12-PGJ3), was effective in targeting LSCs in experimental leukemia. EPA supplementation for 8 weeks resulted in enhanced endogenous production of 12-PGJ3 that was blocked by indomethacin, a cyclooxygenase (COX) inhibitor. Using a murine model of chronic myelogenous leukemia (CML) induced by bone marrow transplantation of BCR-ABL–expressing hematopoietic stem cells, mice supplemented with EPA…

Source: Cancer Prevention ResearchCategory: Cancer & Oncology Authors: Tags: Research Articles Source Type: research

Abstract
There is paucity of data in pediatric Acute Myeloid Leukemia (AML) from developing countries. We analyzed the outcomes of 65 consecutive patients with pediatric AML treated at our centre from January-2008 to May-2013. The median event free survival (EFS) and overall survival (OS) were 12.6 and 14.6 months respectively. Patients with good-risk cytogenetics had a better EFS (p = 0.004) and OS (p = 0.01). Overall, these results are not comparable to that observed in other centres globally and leaves scope for further improvement. This includes implementing allogeneic bone marrow tran…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image